Familial hypercholesterolemia: The lipids or the genes?

Nutrition and Metabolism

Volumn 8, Issue , 2011, Pages

  Fahed, Akl C ^a   Nemer, Georges M ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B100; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROPROTEIN CONVERTASE 1;

AUTOSOMAL RECESSIVE DISORDER; CHOLESTEROL METABOLISM; COST EFFECTIVENESS ANALYSIS; FAMILIAL HYPERCHOLESTEROLEMIA; GENE MUTATION; GENETIC DISORDER; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HEREDITY; HUMAN; NOMENCLATURE; PHENOTYPE; POPULATION; REVIEW;

EID: 79955017150     PISSN: None     EISSN: 17437075     Source Type: Journal    
DOI: 10.1186/1743-7075-8-23     Document Type: Review

References (81)

1. Familial Hypercholesterolemia. J Goldstein H Hobbs M Brown, The Metabolic Basis of Inherited Disease New York: McGraw-Hill, Scriver C, Baudet A, Sly W, Valle D, 2001 2863 2913
2. Clinical features, diagnosis and frequency of familial hypercholesterolemia. AK Khachadurian, Contributions to infusion therapy 1988 23 26 32 2484779
3. The Inheritance of Essential Familial Hypercholesterolemia. AK Khachadurian, The American journal of medicine 1964 37 402 7 10.1016/0002-9343(64)90196-2 14209286
4. A receptor-mediated pathway for cholesterol homeostasis. M Brown J Goldstein, Science 1986 232 34 47 10.1126/science.3513311 3513311 (Pubitemid 16037973)
5. Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. TL Innerarity KH Weisgraber KS Arnold,, et al. Proceedings of the National Academy of Sciences of the United States of America 1987 84 6919 23 10.1073/pnas.84.19.6919 3477815 (Pubitemid 18025501)
6. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. M Abifadel M Varret JP Rabès,, et al. Nature genetics 2003 34 154 6 10.1038/ng1161 12730697 (Pubitemid 36666925)
7. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. CK Garcia K Wilund M Arca,, et al. Science 2001 292 1394 8 10.1126/science.1060458 11326085 (Pubitemid 32476229)
8. Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. J Slack, Lancet 1969 2 1380 2 4188273
9. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group, BMJ 1991 303 893 896 1933004
10. Homozygous familial hypercholesterolemia in Lebanon: A genotype/phenotype correlation. AC Fahed RM Safa FF Haddad,, et al. Molecular genetics and metabolism 2011 102 181 188 10.1016/j.ymgme.2010.11.006 21145767
11. PCSK9 and LDL cholesterol: unraveling the target to design the bullet. P Costet M Krempf B Cariou, Trends in Biochemical Sciences 2008 33 426 434 10.1016/j.tibs.2008.06.005 18672372
12. LXR Regulates Cholesterol Uptake through Idol-dependent Ubiquitination of the LDL Receptor. N Zelcer C Hong R Boyadjian,, et al. Science 2009 325 100 104 10.1126/science.1168974 19520913
13. The LDL receptor gene: a mosaic of exons shared with different proteins. TC Südhof JL Goldstein MS Brown DW Russell, Science 1985 228 815 22 10.1126/science.2988123 2988123 (Pubitemid 15021441)
14. Domain map of the LDL receptor: sequence homology with the epidermal growth factor precursor. DW Russell WJ Schneider T Yamamoto,, et al. Cell 1984 37 577 85 10.1016/0092-8674(84)90388-X 6327078 (Pubitemid 14079052)
15. Biosynthesis of N- and O-linked oligosaccharides of the low density lipoprotein receptor. RD Cumings S Kornfeld WJ Schneider,, et al. Journal of Biological Chemistry 1983 258 15261 73 6317691 (Pubitemid 14178957)
16. Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database. SEA Leigh AH Foster RA Whittall CS Hubbart SE Humphries, Annals of human genetics 2008 72 485 98 10.1111/j.1469-1809.2008.00436.x 18325082 (Pubitemid 351850090)
17. University College London Low Density Lipoprotein Familial Hypercholesterolemia Database. http://www.ucl.ac.uk/ldlr Accessed 15 January 2011
18. The Lebanese allele at the low density lipoprotein receptor locus. Nonsense mutation produces truncated receptor that is retained in endoplasmic reticulum. MA Lehrman WJ Schneider MS Brown,, et al. The Journal of biological chemistry 1987 262 401 10 3025214 (Pubitemid 17000035)
19. Hypercholesterolemia in five Israeli Christian-Arab kindreds is caused by the "Lebanese" allele at the low density lipoprotein receptor gene locus and by an additional independent major factor. A Oppenheim Y Friedlander EJ Dann,, et al. Human genetics 1991 88 75 84 10.1007/BF00204933 1959928
20. The Lebanese mutation as an important cause of familial hypercholesterolemia in Brazil. FL Alberto MS Figueiredo MA Zago AG Arajo JE Dos-Santos, Brazilian journal of medical and biological research 1999 32 739 45 10.1590/S0100-879X1999000600009 10412552 (Pubitemid 129539338)
21. Moderate phenotypic expression of familial hypercholesterolemia in Tunisia. A Jelassi A Slimani I Jguirim,, et al. Clinical Chimica Acta 2010 411 735 738 10.1016/j.cca.2010.02.008
22. Genetic susceptibility to heart disease in Canada: lessons from patients with familial hypercholesterolemia. RA Hegele, Genome/National Research Council Canada 2006 49 1343 50 (Pubitemid 46640322)
23. Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. LF Soria EH Ludwig HR Clarke,, et al. Proceedings of the National Academy of Sciences of the United States of America 1989 86 587 91 10.1073/pnas.86.2.587 2563166 (Pubitemid 19037786)
24. Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia. NB Myant, Atherosclerosis 1993 104 1 18 10.1016/0021-9150(93)90171-P 8141833 (Pubitemid 24035628)
25. Identification and haplotype analysis of apolipoprotein B-100 Arg3500 - >Trp mutation in hyperlipidemic Chinese. DY Tai JP Pan GJ Lee-Chen, Clinical chemistry 1998 44 1659 65 9702952
26. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. J Cohen A Pertsemlidis IK Kotowski,, et al. Nature genetics 2005 37 161 5 10.1038/ng1509 15654334
27. Mutations and Polymorphisms in the Proprotein Convertase Subtilin Kexin 9 (PCSK9) Gene in Cholesterol Metabolism and Disease. M Abifadel JP Rabes M Devillers,, et al. Human Mutation 2009 30 520 529 10.1002/humu.20882 19191301
28. PCSK9 as a therapeutic target for dyslipidemia. NG Seidah, Expert opinion on therapeutic targets 2009 13 19 28 10.1517/14728220802600715 19063703
29. PCSK9 as a therapeutic target in atherosclerosis. AJ Marian, Current Atherosclerosis Reports 2010 12 151 4 10.1007/s11883-010-0099-2 20425252
30. PCSK9: an emerging target for treatment of hypercholesterolemia. CJ Duff NM Hooper, Expert opinion on therapeutic targets 2011 15 2 157 68 Epub 2011 Jan 5 10.1517/14728222.2011.547480 21204732
31. Use of homozygosity mapping to identify a region on chromosome 1 bearing a defective gene that causes autosomal recessive homozygous hypercholesterolemia in two unrelated families. ER Eden RP Naoumova JJ Burden,, et al. American Journal of Human Genetics 2001 68 653 60 10.1086/318795 11179013 (Pubitemid 32202760)
32. Genetics, clinical phenotype, and molecular cell biology of autosomal recessive hypercholesterolemia. AK Soutar RP Naoumova LM Traub, Arteriosclerosis, thrombosis, and vascular biology 2003 23 1963 70 10.1161/01.ATV.0000094410.66558.9A 12958046 (Pubitemid 37433187)
33. A novel ARH splice site mutation in a Mexican kindred with autosomal recessive hypercholesterolemia. S Canizales-Quinteros CA Aguilar-Salinas A Huertas-Vasquez,, et al. Human Genetics 2005 116 114 20 10.1007/s00439-004-1192- 9 15599766 (Pubitemid 40057922)
34. A novel Thr56Met mutation of the autosomal recessive hypercholesterolemia gene associated with hypercholesterolemia. K Harada Y Miyamoto H Morisaki,, et al. Journal of atherosclerosis and thrombosis 2010 17 131 40 20124734
35. ApoB-100 R3500Q mutation in the Lebanese population: prevalence and historical review of the literature. AS Sabbagh RT Daher ZK Otrock,, et al. Molecular biology reports 2007 34 267 70 10.1007/s11033-006-9041-7 17160438 (Pubitemid 47624288)
36. Autosomal recessive hypercholesterolemia (ARH) and homozygous familial hypercholesterolemia (FH): a phenotypic comparison. L Pisciotta C Priore Olivia GM Pes,, et al. Atherosclerosis 2006 188 398 405 10.1016/j.atherosclerosis.2005. 11.016 16343504 (Pubitemid 44301145)
37. A Q136Stop Mutation in the ARH gene causing autosomal recessive hypercholesterolaemia with severely delayed LDL catabolism. UJ Tietge J Genschel HH Schmidt, Journal of Internal Medicine 2003 253 582 583 10.1046/j.1365-2796. 2003.01139.x 12702036 (Pubitemid 36543298)
38. Autosomal recessive hypercholesterolaemia: long-term follow up and response to treatment. RP Naoumova C Neuwirth P Lee,, et al. Atherosclerosis 2004 174 165 72 10.1016/j.atherosclerosis.2004.01.020 15135266 (Pubitemid 38595453)
39. The molecular basis of familial hypercholesterolemia in Lebanon: spectrum of LDLR mutations and role of PCSK9 as a modifier gene. M Abifadel JP Rabès S Jambart,, et al. Human Mutation 2009 30 682 91 10.1002/humu.21002 19319977
40. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia. D Allard S Amsellem M Abifadel,, et al. Human Mutation 2005 26 497 10.1002/humu.9383 16211558
41. Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia. L Pisciotta C Priore Olivia AB Cefalu,, et al. Atherosclerosis 2006 186 433 40 10.1016/j.atherosclerosis.2005.08.015 16183066
42. Multiplex ligation-dependent probe amplification of LDLR enhances molecular diagnosis of familial hypercholesterolemia. J Wang MR Ban RA Hegele, Journal of Lipid Research 2005 46 366 72 15576851 (Pubitemid 40271101)
43. MLPA and MAPH: new techniques for detection of gene deletions. LN Sellner GR Taylor, Human Mutation 2004 23 413 9 10.1002/humu.20035 15108271 (Pubitemid 38569212)
44. Phenotypic variability in familial hypercholesterolaemia: an update. AC Jansen S van Wissen JC Defesche,, et al. Current Opinion in Lipidology 2002 13 165 71 10.1097/00041433-200204000-00008 11891419 (Pubitemid 34280768)
45. Fh-Souassi: a founder frameshift mutation in exon 10 of the LDL-receptor gene, associated with a mild phenotype in Tunisian families. MN Slimane S Lestavel X Sun,, et al. Atherosclerosis 2001 154 557 65 10.1016/S0021-9150(00) 00572-4 11257256 (Pubitemid 32232152)
46. Familial hypercholesterolemia and response to statin therapy according to LDLR genetic background. DM Choumerianou GVZ Dedoussis, Clinical chemistry and laboratory medicine: CCLM/FESCC 2005 43 793 801 10.1515/CCLM.2005.134 (Pubitemid 41461152)
47. Apolipoprotein polymorphisms and familial hypercholesterolemia. GVZ Dedoussis, Pharmacogenomics 2007 8 1179 89 10.2217/14622416.8.9.1179 17924833 (Pubitemid 47578227)
48. Familial hypercholesterolemia and coronary heart disease: a HuGE association review. MA Austin CM Hutter RL Zimmern S Humphries, American Journal of Epidemiology 2004 160 421 9 10.1093/aje/kwh237 15321838 (Pubitemid 39166974)
49. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. AC Jansen ES van Aalst-Cohen MW Tanck,, et al. Journal of Internal Medicine 2004 256 482 90 10.1111/j.1365-2796.2004.01405.x 15554949 (Pubitemid 39577582)
50. Commentary: Lipoprotein (a) and atherosclerosis. A Clarke, International Journal of Epidemiology 2011 40 2 478 9 Epub 2011 Feb 17 10.1093/ije/dyr015 21330345
51. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. F Civeira, Atherosclerosis 2004 173 55 68 10.1016/j.atherosclerosis.2003.11.010 15177124 (Pubitemid 38224196)
52. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group, BMJ (Clinical research ed.) 1991 303 893 6
53. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. RR Williams SC Hunt MC Schumacher, American Journal of Cardiology 1993 72 171 6 10.1016/0002-9149(93)90155-6 8328379 (Pubitemid 23205873)
54. Screening for familial hypercholesterolaemia. Early identification and treatment of patients is important. P Nicholls I Young K Lyttle,, et al. BMJ 2001 322 1062 10.1136/bmj.322.7293.1062 11349663
55. Cholesterol screening in children and adolescents. TB Newman AM Garber, Pediatrics 2000 105 637 638 10.1542/peds.105.3.637 10699121 (Pubitemid 30129683)
56. Statins for children with familial hypercholesterolemia. A Vuorio J Kuoppala PT Kovanen,, et al. Cochrane Database of Systematic Reviews 2010 7 D006401
57. Integrating provision of specialist lipid services with cascade testing for familial hypercholesterolaemia. BN Datta IFW McDowell A Rees, Current Opinion in Lipidology 2010 21 366 371 10.1097/MOL.0b013e32833c14e2 20613514
58. Cascade genetic screening for familial hypercholesterolemia. TP Leren, Clinical Genetics 2004 66 483 487 10.1111/j.1399-0004.2004.00320.x 15521974 (Pubitemid 39562009)
59. No certain predictors for mutation status in a Danish cohort with familial hypercholesterolemia: a descriptive study. M Nybo K Brusgaard AB Hansen, Clinical biochemistry 2007 40 1347 52 10.1016/j.clinbiochem.2007.09.012 17961529 (Pubitemid 350153642)
60. Molecular diagnosis of familial hypercholesterolemia: an important tool for cardiovascular risk stratification. AC Alves AM Medeiros V Francisco,, et al. Portugese Journal of Cardiology 2010 29 907 21
61. Familial Hypercholesterolemia. A Report of a WHO consultation Part I. Paris 1997
62. Molecular epidemiology of familial hypercholesterolaemia. JC Defesche JJ Kastelein, Lancet 1998 352 1643 4 9853432 (Pubitemid 28526118)
63. Child-parent screening for familial hypercholesterolaemia: screening strategy based on a meta-analysis. DS Wald JP Bestwick NJ Wald, BMJ 2007 335 599 10.1136/bmj.39300.616076.55 17855284
64. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. MA Umans-Eckenhausen JC Defesche EJ Sijrbrands,, et al. Lancet 2001 357 165 8 10.1016/S0140-6736(00)03587-X 11213091 (Pubitemid 32108086)
65. Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands. D Wonderling MA Umans-Eckenhausen D Marks,, et al. Seminars in vascular medicine 2004 4 97 104 15199439 (Pubitemid 38393297)
66. Defining the challenges of FH Screening for familial hypercholesterolemia. JC Defesche, Journal of Clinical Lipidology 2010 4 338 341 10.1016/j.jacl.2010.08.022 21122674
67. Application of molecular genetics for diagnosing familial hypercholesterolemia in Norway: results from a family-based screening program. TP Leren T Manshaus U Skovholt,, et al. Seminars in vascular medicine 2004 4 75 85 15199436 (Pubitemid 38393294)
68. Diagnosis of familial hypercholesterolemia in general practice using clinical diagnostic criteria or genetic testing as part of cascade genetic screening. TP Leren TH Finborud TE Manshaus,, et al. Community Genetics 2008 11 26 35 10.1159/000111637 18196915
69. Familial hypercholesterolemia in Spain: case-finding program, clinical and genetic aspects. M Pocovi F Civeira R Alonso,, et al. Seminars in Vascular Medicine 2004 4 67 74 15199435 (Pubitemid 38393293)
70. Comparison of Genetic Versus Clinical Diagnosis in Familial Hypercholesterolemia. F Civeira E Ros E Jarauta,, et al. The American Journal of Cardiology 2008 102 1187 93 10.1016/j.amjcard.2008.06.056 18940289
71. The Cardiac Society of Australia and New Zealand Guidelines for the Diagnosis and Management of Familial Hypercholesterolemia 2010. http://www.csanz.edu.au/LinkClick.aspx?fileticket=EOvAvk2jApc%3d&tabid=148 Accessed 15 January 2011
72. Preventing cardiovascular disease: a review of the effectiveness of identifying the people with familial hypercholesterolaemia in New Zealand. LA Muir PM George AD Laurie,, et al. New Zealand Medical Journal 2010 123 97 102 21326404
73. Wales Familial Hypercholesterolemia Testing Service. http://www.fhwales. co.uk Accessed 15 January 2011
74. Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project. A Taylor D Wang K Patel,, et al. Clinical Genetics 2010 77 572 580 20236128
75. Molecular genetic testing for familial hypercholesterolemia in the Netherlands: a stepwise screening strategy enhances the mutation detection rate. MP Lombardi EJ Redeker DH van Gent,, et al. Genetic Testing 2006 10 77 84 10.1089/gte.2006.10.77 16792510 (Pubitemid 43993292)
76. Molecular genetic analysis of 1053 Danish individuals with clinical signs of familial hypercholesterolemia. K Brusgaard P Jordan H Hansen,, et al. Clinical Genetics 2006 69 277 283 10.1111/j.1399-0004.2006.00585.x 16542394 (Pubitemid 43349012)
77. The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population. D Damgaard ML Larsen PH Nissen,, et al. Atherosclerosis 2005 180 155 160 10.1016/j.atherosclerosis.2004.12.001 15823288
78. Evaluation of high-resolution melting analysis for screening the LDL receptor gene. AD Laurie PM George, Clinical Biochemistry 2009 42 528 535 10.1016/j.clinbiochem.2008.11.015 19118540
79. Genetic screening of patients with familial hypercholesterolaemia (FH): a New Zealand perspective. AD Laurie RS Scott PM George, Atherosclerosis Supplements 2004 5 13 15 15556094 (Pubitemid 39535761)
80. Systematic Family Screening for Familial Hypercholesterolemia in Iceland. B Thorsson G Sigurdsson V Gudnason, Arteriosclerosis Thrombosis and Vascular Biology 2003 23 335 338 10.1161/01.ATV.0000051874.51341.8C (Pubitemid 36231949)
81. Implementation of cascade testing for the detection of familial hypercholesterolaemia. SG Hadfield SE Humphries, Current Opinion in Lipidology 2005 16 428 433 10.1097/01.mol.0000174152.76554.d6 15990592 (Pubitemid 41017627)